Partner Therapeutics, Inc. (PTx), a Boston, MA-based oncology company, closed a $60m Series A financing.
Backers included Perceptive Advisors, Adams St. Partners and MidCap Financial.
The company will use the funds to launch build a pipeline of oncology programs and the development and commercial operations of the business.
Led by CEO Robert Mulroy, PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer. PTx’s development focus spans the entire range of cancer therapy from primary treatments to supportive care.
The company will seek to build its product portfolio through the acquisition of programs with the promise to deliver on improved health and economic outcomes.